MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

866.626.6847

Atenolol (Tenormin®)

Selected References:

  • Bayliss H, et al. 2002. Anti-hypertensive drugs in pregnancy and fetal growth: evidence for “pharmacological programming” in the first trimester? Hypertens Pregnancy; 21:161-74.
  • Bratton S, et al. 2024. Does atenolol use during pregnancy cause small for gestational age neonates? A meta-analysis. Journal of Perinatal Medicine, 52(8), 858-862.
  • Caton AR, et al. 2009. Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations. Hypertension; 54(1):63-70.
  • Easterling TR, et al. 1999. Prevention of preeclampsia: a randomized trial of atenolol in hyperdynamic patients before onset of hypertension. Obstet Gynecol; 93(5 Pt 1):725-733.
  • Eyal S, et al. 2010. Atenolol pharmacokinetics and excretion in breast milk during the first 6 to 8 months postpartum. J Clin Pharmacol; 50:1301-9.
  • Fogari R, et al. 1998. Sexual function in hypertensive males treated with lisinopril or atenolol: a cross-over study. American journal of hypertension. 11(10): 1244-47.
  • Fogari R, et al. 2002. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. Eur J Clin Pharmacol; 58: 177–80.
  • Guo D, et al. 2017. Hypertension and male fertility. The world journal of men’s health; 35.2: 59-64.
  • Kirch W & Görg KG. 1982. Clinical pharmacokinetics of atenolol–a Circ J. 80(10): 2221-6.
  • Lip GY, et al. 1997. Effect of atenolol on birth weight. Am J Cardiol; 79: 1436-8.
  • Lwin EMP, et al. 2018. Estimation of atenolol transfer into milk and infant exposure during its use in lactating women. J Hum Lact; 34(3):592-599.
  • Lydakis C, et al. 1999. Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens; 12:541-7.
  • Mayo Foundation for Medical Education and Research, 2022, Atenolol (Oral Route), Mayo 1: 1-10
  • Montan S, et al. 1987. Fetal and uteroplacental haemodynamics during short term atenolol treatment of hypertension in pregnancy. Br J Obstet Gynaecol; 94:312-317.
  • Orbach H, et al. 2013. Hypertension and antihypertensive drugs in pregnancy and perinatal outcomes. Am J Obstet Gynecol; 208(4): 301.e1-301.e6.
  • Räsänen J, Jouppila P. 1995. Uterine and fetal hemodynamics and fetal cardiac function after atenolol and pindolol infusion. A randomized study. Eur J Obstet Gynecol Reprod Biol; 62:195-201.
  • Reynolds B, et al. 1984. First year of life after the use of atenolol in pregnancy associated with hypertension. Arch Dis Child; 59(11):1061-1063.
  • Rubin PC, et al. 1983. Placebo-controlled trial of atenolol in treatment of pregnancy-associated hypertension. Lancet; 1:431-4.
  • Rubin PC, et al. 1984. Obstetric aspects of the use in pregnancy-associated hypertension of the beta-adrenoceptor antagonist atenolol. Am J Obstet Gynecol; 150:389-92.
  • Schimmel M, et al. 1989. Toxic effect of atenolol consumed during breast feeding. J Pediatrics; 114:476-8.
  • Tabacova S, et al. 2003. Atenolol developmental toxicity: animal-to-human comparisons. Birth Defects Res; 67:181-92.
  • Tanaka K, 2016. Beta-blockers and fetal growth restriction in pregnant women with cardiovascular
  • Thorley KJ, McAnish J. 1983. Levels of the beta-blockers atenolol and propranolol in the breast milk of women treated for hypertension in pregnancy. Biopharm Drug Dispos; 4:229-301.
  • White WB, et al. 1984. Atenolol in human plasma and breast milk. Obstet Gynecol; 63 (S1):42-44. European journal of drug metabolism and pharmacokinetics, 7 (2), 81–91. https://doi.org/10.1007/BF03188723.

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.